Akorn-Strides files tenth aNDA submission

By Elaine Rigoli

Tampa, Fla., Aug. 25 - Akorn-Strides, LLC, a joint venture company formed between Akorn, Inc. and Strides Arcolab Ltd., has submitted its 10th abbreviated New Drug Application with the Office of Generic Drugs.

"We are delighted with the pace of filings through the joint venture with Akorn. We are confident of playing a significant role providing a strong pipeline and supplies to convert Akorn-Strides into a significant hospital player in the U.S.," executive vice chairman and managing director Arun Kumar said in a news release.

The first aNDA submission for the Akorn-Strides joint venture was filed in April.

Based in Buffalo Grove, Ill., Akorn manufactures and markets sterile specialty pharmaceuticals.

Strides is a generic pharmaceuticals company based in Mumbai, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.